Celcuity announced positive Phase 3 VIKTORIA-1 trial results showing gedatolisib combination regimens reduced disease progression risk by 50% compared to alpelisib in PIK3CA mutant HR+/HER2- breast cancer patients. The results represent a potential major advancement for the company's lead candidate and could support future regulatory approval discussions.